MelissaA.HughesMD

Anesthesiology • Richmond, IN

Physician

Join to view full profile

Are you Dr. Hughes?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 48 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1100 Reid Pkwy
Richmond, IN 47374
Phone+1 765-935-8747

Fax+1 765-983-3023
Is this information wrong?

Summary

Dr. Melissa Hughes, MD is a board certified anesthesiologist in Richmond, Indiana. She is currently licensed to practice medicine in Indiana, Kentucky, and Arkansas. She is affiliated with Reid Health.

Education & Training

University of Arkansas for Medical SciencesResidency, Anesthesiology, 2006 - 2010
University of Arkansas For Medical Sciences College of MedicineClass of 2006

Certifications & Licensure

IN State Medical License 2022 - 2025
KY State Medical License 2024 - 2025
AR State Medical License 2010 - 2022
American Board of Anesthesiology Anesthesiology

Publications & Presentations

PubMed

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.
Vaz-Luis, I.,Hughes, M. E.,Cronin, A.,Rugo, H. S.,Edge, S. B.,Moy, B.,Theriault, R. L.,Hassett, M. J.,Winer, E. P.,Lin, N. U.> ;Breast Cancer Res. Treat.. 2016 Feb 13
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng, Y. D.,Uno, H.,Hughes, M. E.,Niland, J. C.,Wong, Y. N.,Theriault, R.,Blitzblau, R. C.,Moy, B.,Breslin, T.,Edge, S. B.,Hassett, M. J.,Punglia, R. S.> ;Int. J. Radiat. Oncol. Biol. Phys.. 2015 Oct 16
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.
Vaz-Luis, I.,Hughes, M. E.,Cronin, A. M.,Rugo, H. S.,Edge, S. B.,Moy, B.,Theriault, R. L.,Hassett, M. J.,Winer, E. P.,Lin, N. U.> ;Cancer. 2015 Mar 12
Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience.
Wolff, A. C.,Blackford, A. L.,Visvanathan, K.,Rugo, H. S.,Moy, B.,Goldstein, L. J.,Stockerl-Goldstein, K.,Neumayer, L.,Langbaum, T. S.,Theriault, R. L.,Hughes, M. E.,W...> ;J. Clin. Oncol.. 2014 Dec 24
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.
Vaz-Luis, I.,Ottesen, R. A.,Hughes, M. E.,Mamet, R.,Burstein, H. J.,Edge, S. B.,Gonzalez-Angulo, A. M.,Moy, B.,Rugo, H. S.,Theriault, R. L.,Weeks, J. C.,Winer, E. P.,L...> ;J. Clin. Oncol.. 2014 Jun 04
Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ.
Greenberg, C. C.,Habel, L. A.,Hughes, M. E.,Nekhlyudov, L.,Achacoso, N.,Acton, L.,Schrag, D.,Jiang, W.,Edge, S.,Weeks, J. C.,Punglia, R. S.> ;Ann. Surg. Oncol.. 2014 May 27
Epsilon toxin is essential for the virulence of Clostridium perfringens type D infection in sheep, goats, and mice.
Garcia, J. P.,Adams, V.,Beingesser, J.,Hughes, M. L.,Poon, R.,Lyras, D.,Hill, A.,McClane, B. A.,Rood, J. I.,Uzal, F. A.> ;Infect. Immun.. 2013 Jul
Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Co...
Freedman, R. A.,Hughes, M. E.,Ottesen, R. A.,Weeks, J. C.,He, Y.,Wong, Y. N.,Theriault, R.,Keating, N. L.> ;Cancer. 2013 Feb 15
Institutional variation in the surgical treatment of breast cancer: a study of the NCCN.
Greenberg, C. C., Lipsitz, S. R., Hughes, M. E., Edge, S. B., Theriault, R., Wilson, J. L., Carter, W. B., Blayney, D. W., Niland, J., Weeks, J. C.> ;Ann Surg. 2011 Aug
Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
Wong, Y. N., Ottesen, R. A., Hughes, M. E., Niland, J. C., Theriault, R., Edge, S. B., Blayney, D., Weeks, J. C.> ;Oncologist. 2011
The impact of breast reconstruction on the delivery of chemotherapy.
Alderman, A. K., Collins, E. D., Schott, A., Hughes, M. E., Ottesen, R. A., Theriault, R. L., Wong, Y. N., Weeks, J. C., Niland, J. C., Edge, S. B.> ;Cancer. 2010 Apr 1
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Svahn, T. H., Niland, J. C., Carlson, R. W., Hughes, M. E., Ottesen, R. A., Theriault, R. L., Edge, S. B., Schott, A. F., Bookman, M. A., Weeks, J. C.> ;J Natl Compr Canc Netw. 2009 Feb 01
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y. N., Wilson, J., Carter, W. B., Blayney, D. W., Weeks, J. C.> ;J Clin Oncol. 2008 Dec 01
Selecting high priority quality measures for breast cancer quality improvement.
Hassett, M. J., Hughes, M. E., Niland, J. C., Ottesen, R., Edge, S. B., Bookman, M. A., Carlson, R. W., Theriault, R. L., Weeks, J. C.> ;Med Care. 2008 Aug
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.
Punglia, R. S., Hughes, M. E., Edge, S. B., Theriault, R. L., Bookman, M. A., Wilson, J. L., Ottesen, R. A., Niland, J. C., Weeks, J. C.> ;Int J Radiat Oncol Biol Phys. 2008 Dec 1
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network.
Christian, C. K., Niland, J., Edge, S. B., Ottesen, R. A., Hughes, M. E., Theriault, R., Wilson, J., Hergrueter, C. A., Weeks, J. C.> ;Ann Surg. 2006 Feb
The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers.
Buchholz, T. A., Theriault, R. L., Niland, J. C., Hughes, M. E., Ottesen, R., Edge, S. B., Bookman, M. A., Weeks, J. C.> ;J Clin Oncol. 2006 Jan 20
Join now to see all

Hospital Affiliations

Mercy Hospital Fort SmithFort Smith, Arkansas
Reid HealthRichmond, Indiana